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Abstract Lysosomal storage diseases are inherited metabolic
disorders caused by genetic defects causing deficiency of
various lysosomal proteins, and resultant accumulation of
non-degraded compounds. They are multisystemic diseases,
and in most of them (>70 %) severe brain dysfunctions are
evident. However, expression of various phenotypes in par-
ticular diseases is extremely variable, from non-neuronopathic
to severely neurodegenerative in the deficiency of the same
enzyme. Although all lysosomal storage diseases are mono-
genic, clear genotype-phenotype correlations occur only in
some cases. In this article, we present an overview on various
factors and processes, both general and specific for certain
disorders, that can significantly modulate expression of phe-
notypes in these diseases. On the basis of recent reports
describing studies on both animal models and clinical data,
we propose a hypothesis that efficiency of production of
compounds that cannot be degraded due to enzyme deficiency
might be especially important in modulation of phenotypes of
patients suffering from lysosomal storage diseases.
Keywords Inherited metabolic diseases . Lysosomal storage
diseases . Neuronopathic forms of heritable disorders .
Genotype-phenotypecorrelations .Factorsmodulatingdisease
severity
Introduction
There are several thousand inherited diseases identified to date
(Korf and Rehm 2013), among which many affect brain
functions. An example is a group of metabolic disorders
caused by genetically determined dysfunctions of enzymes
or non-enzymatic proteins required for functions of lyso-
somes, known as lysosomal storage diseases or LSDs (for a
recent review see Platt et al. 2012). All LSDs are monogenic
disorders, and each of them is characterized by deficiency in
activity of one of polypeptides involved in degradation of
particular macromolecular compounds or in other lysosomal
functions. Hence, accumulation of certain undegraded com-
pound(s) occurs in each LSD, and due to continuous synthesis
of these compounds, the disease has a progressive character.
In fact, clinical symptoms of some LSDs appear as late as at
the age of a few or even several years, but then they become
more and more severe. LSDs are classified on the basis of the
nature of accumulated compound(s) and the kind of deficient
enzyme, encoded by a corresponding gene. Thus, over 50
types and subtypes of LSDs are currently recognized
(reviewed by Cox and Cachon-Gonzalez 2012). It is worth
noting that – contrary to early hypotheses – despite the fact
that development of each LSD depends on dysfunction (or
deletion) of particular gene and resultant deficiency of activity
of particular gene product, it is not obvious whether primary
storage of various materials are primary causes of the LSDs.
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LSDs are amongst the most commonly confirmed diagno-
ses of neurodegeneration, reaching as many as 45 % of cases
(Verity et al. 2010). In fact, most of LSD types (>70 %) result
in severe dysfunctions of central nervous system, while pa-
tients suffering from other LSDs may be non-neuronopathic
or their neurological symptoms may be mild (reviewed by
Jardim et al. 2010; Arfi et al. 2012). Although neuronopathy
depends on insufficient degradation of certain compounds, it
is still unclear whether symptoms resulting from central ner-
vous system involvement are due to storage material in extra-
cellular matrix or abnormality of the extracellular matrix itself
(as effects of reactions secondary to the storage), or both. For
instance, severity of neurodegenerative sphingolipidoses may
be associated to changes of the properties of plasma mem-
branes, including trafficking defects of membrane lipids and
proteins (Eckhardt 2010). Another interesting example is
Gaucher disease, the most common LSD, which is caused
by dysfunction of glucocerebrosidase and resultant accumu-
lation of glucocerebroside that cannot be cleaved to glucose
and ceramide (Sidransky 2004). A clinical link between this
disease and Parkinson disease has been described, which was
expressed as relatively early symptoms of parkinsonism in
Gaucher disease patients (Sidransky 2005). This suggested that
mutations in theGBA1 gene (coding for the glucocerebrosidase),
and resultant alterations in sphingolipid metabolism, may con-
tribute to biochemical changes found in Parkinson disease. More
recent studies indicated that a lack of the glucocerebrosidase
activity compromises lysosomal protein degradation and causes
accumulation of α-synuclein, which results in neurotoxicity
(Mazzulli et al. 2011). In fact, appearance of aggregates of this
protein is characteristic for Parkinson disease neurons (for a
review, see Olanow and Brundin 2013).
Despite our incomplete understanding of the primary
cause(s) of cell, tissue and organ dysfunctions in LSD, it is
well documented that clinical symptoms arising from accu-
mulation of incomplete degradation of the same substance
which hydrolysis is inhibited at various stages can be
significantly different. For example, brain disease in
patients suffering from both mucopolysaccharidosis type I
(MPS I) and mucopolysaccharidosis type III (subtypes A, B, C
and D) (MPS III subtypes A to D) results from accumulation of
metabolites of heparan sulfate (HS), one of glycosaminoglycans
(GAGs) (for a recent review, see Muenzer 2011). However, in
MPS I patientswith neuronopathy, despite problemswith learning
and cognitive deterioration, little or no behavioral problems occur
(reviewed by Campos and Monaga 2012). These patients are
usually placid, gentle, calm, and often over-careful, even if
cognitive deterioration is severe. On the other hand, MPS III
patients (all subtypes), develop an aggressive behavior, they are
hyperactive, and have usually severe sleeping defects.More-
over, these patients appear to ignore any danger, and their
behavior suggests intensive action without any particular sense
(discussed by Valstar et al. 2008; Wijburg et al. 2013). It was
suggested that certain chemical moieties occurring at the ends
of incompletely degraded HS molecules may determine char-
acteristic behavioral disturbances, perhaps due to chemical
reactions interfering with functions of neurons in the brain
(Wegrzyn et al. 2010). In fact, HS degradation is inhibited at
various stages in patients suffering fromMPS I andMPS III A-
D, and thus, different metabolites accumulate in each of these
diseases.
Interestingly, there is a huge variability in patients’ pheno-
types not only between different LSD, but also between
different patients suffering from the same type of disease. A
classical example is MPS I, mentioned above. This disease is
caused by mutations in the IDUA gene, coding for α-L-
iduronidase, and resulting in lysosomal storage of two GAGs:
HS and dermatan sulfate (DS). The spectrum of neuronopathic
symptoms of this disease is from severe mental and cognitive
disability to completely normal intelligence and behavior, in-
cluding all intermediate phenotypes (note that somatic symp-
toms occur in all MPS I patients, but with different severity).
In fact, deficiency of α-L-iduronidase has been initially de-
scribed as two different diseases, Hurler disease (MPS I) and
Scheie disease (mucopolysaccharidosis type V or MPS V).
Subsequent studies demonstrated that both disorders are
caused by mutations in the same gene, IDUA , and led to the
conclusion that they are just two extreme clinical phenotypes
of the same metabolic disease (summarized by Lashford et al.
1999).
The obvious question appearing in the light of the above
mentioned variability in clinical spectra of one disease is: what
is responsible for such big differences in phenotypes of pa-
tients suffering from dysfunction of just one gene? Perhaps
surprisingly, we are still not able to answer this question
precisely, despite unquestionable advance in understanding
molecular, cellular and physiological mechanisms of LSDs.
In this article, we will summarize our current knowledge on
genotype-phenotype correlations in these diseases as well as
physiological and environmental factors modulating effects of
mutations in single genes.
Genotype-phenotype correlations in LSDs
Determination of a genotype-phenotype correlation is the
primary approach in attempts to understand variability of
any monogenic disease, and to predict the level of symptoms’
severities if early diagnosis was made (Lyonnet et al. 2006).
Therefore, it is not a surprise that many articles were published
in which authors tried to understand genotype-phenotype
correlations in different inherited metabolic diseases, includ-
ing LSDs. However, contrary to an early assumption that
knowing mutation(s) in the affected gene one should be able
to predict patient’s phenotype (highlighted and discussed by
Silverman and Mahadevan 2005), after years of studies, it
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appears that such a scenario is possible only in some cases,
and often the clinical phenotype is weakly related to the
particular mutation (reviewed by Lippi and Favaloro 2009).
In LSDs, a general scheme can be presented that non-sense
mutations or other mutations that result is a complete lack of
activity of corresponding genes’ products (like most of dele-
tions, insertions, and other types of gene rearrangements),
called null mutations, cause severe phenotypes (for a review
and discussion, see Filocamo and Morrone 2011). This is also
true for diseases in which neuronopathy occurs only in a
fraction of patients, like MPS I or Gaucher disease. In these
cases, null mutations cause a neuronopathic form of the
disease, while mutations allowing an appearance of a residual
enzyme activity (like missense mutations) may result in atten-
uated, non-neuronopathic phenotypes (Terlato and Cox 2003;
Vitner and Futerman 2013). Nevertheless, while the former
rule is usually true, the latter one is often false, as there are
many examples of severe neuronopathic phenotypes of pa-
tients bearing missense mutations (among many reports on
this topic, see for example, Chkioua et al. 2011; Michelakakis
et al. 2006).
There are many reports in the literature describing large
problems in finding unambiguous genotype-phenotype corre-
lations in LSDs. Below, we will discuss only very few of
them, just to exemplify the level of complication of the
problem.
Fabry disease is an X-linked LSD, in which mutations in a
gene coding forα-galactosidase A (α-GAL) result in impaired
degradation of certain glycoconjugates and accumulation of
globotriaosylceramide (Gb3) in various tissues including kid-
neys, heart, and the nervous system. As discussed by Ries and
Gal (2006), there is a high degree of clinical variability both
among patients from the same family and among those from
unrelated families with the same mutation. Therefore, in this
disease, knowing the mutation type in the α-GAL gene is of
relatively little help for prediction of patient’s phenotype.
Moreover, since the same genotype can result in different
phenotypes, it is clear that other factors must influence the
disease expression.
There are 3 clinical forms of Gaucher disease
(glucocerebrosidase deficiency): type 1 is restricted to visceral
and/or skeletal involvement with no brain dysfunction, type 2
is a neuronopathic form characterized by severe central ner-
vous system involvement in infancy, and type 3 is an inter-
mediate form, with milder neuronopathy. In Gaucher disease,
some clear genotype-phenotype correlations could be detect-
ed. The N370S mutation (in either homozygotic or complex
heterozygotic form) is restricted to patients with type 1 dis-
ease, while homozygosity for the L444P mutation is highly
associated with type 3 disease (Koprivica et al. 2000). How-
ever, among L444P homozygous patients, a high variability in
phenotypes was reported, though all were classified within
type 3 (Goker-Alpan et al. 2005). Another mutation, R463C,
was found in patients with type 1 as well as with type 3 disease
(Koprivica et al. 2000). Analysis of many kinds of mutations
in the glucocerebrosidase gene of patients suffering from
various types of Gaucher disease revealed a considerable
genotypic heterogeneity among clinically similar patients,
and significantly different phenotypes among patients with
the same mutations (Sidransky 2004). An extremely interest-
ing case of monozygotic twin sisters has been reported by
Biegstraaten et al. (2011). These sisters, both being homozy-
gous for the N188S mutation, expressed extremely different
phenotypes of Gaucher disease. One of them had severe
visceral involvement, epilepsy, and a cerebellar syndrome,
while the second developed only type 1 diabetes mellitus with
no other symptoms of Gaucher disease. Equally intriguing
observations were reported earlier by Lachmann et al.
(2004), where two pairs of twins have been described. In the
first pair, from two monozygotic sisters homozygous for the
N370S mutation, only one developed Gaucher disease symp-
toms while the second remained asymptomatic for this disease
until she died at the age of 84 years. The second pair consisted
of dizygotic twins being compound heterozygotes for the
N370S and L444P alleles, fromwhich only one has developed
Gaucher disease symptoms by the age of 57 years. All the
results mentioned in this paragraph indicate that although
some genotype-phenotype correlations are evident in Gaucher
disease, there are many mutations which effects must be
modified by other factors to result in such a variability of
patients’ phenotypes.
Mutations in both alleles of the GAA gene, coding for acid
α-glucosidase, result in accumulation of glycogen and clinical
symptoms described as Pompe disease. Variability of pheno-
types is large in this disease, from a very severe infantile form
to more attenuated ones which clinical expression may occur
in adults. Genotype-phenotype correlation in Pompe disease is
quite strict relative to some other LSDs, as the severe infantile
form is restricted to mutations leading to a total lack of GAA
expression or a complete lack of produced acid α-glucosidase
(Kroos et al. 2012) in both alleles. However, some other
genotypes, like c.-32-13 T > G/null , result in very different
phenotypes of patients (Kroos et al. 2012).
Mucopolysaccharidosis type VI (MPS VI) is a disorder
caused by deficiency in N-acetylgalactosamine 4-sulfatase
(arylsulfatase B) activity due to mutations in the ARSB gene.
This leads to the storage of dermatan sulfate (DS), one of
GAGs. Amongst over 130 pathogenic mutations described in
theARSB gene, most aremissensemutations (Saito et al. 2012).
Despite the fact that some genotype-phenotype correlations
have been clear, our understanding of effects of particular
changes in the sequence of ARSB on the disease severity is
far from being complete (Valayannopoulos et al. 2010; Brands
et al. 2013). Interestingly, although MPS VI usually affects
many organs, a specific, predominantly cardiac, phenotype
has been described recently, which is associated with the
Metab Brain Dis
homozygous R152Wmutation in the ARSB gene (Jurecka et al.
2011, 2013). However, molecular mechanism of such an ex-
pression of this disease in R152W/ R152W patients is
unknown.
In summary, while some genotype-phenotype relationships
are evident in LSDs, there are plenty of examples that the
same mutation may result in very different clinical symptoms
and different progress of the disease. Moreover, level of
residual activity of the deficient enzyme often does not corre-
spond to the disease severity.
General physiological processes and environmental
factors influencing LSDs
Since genotype-phenotype correlations cannot be determined
in many cases of LSDs, it became clear that other factors or
processes must influence severity of symptoms occurring in
particular patients. In fact, publications from last several years
indicated that there are various physiological processes and
environmental factors that can significantly modify the course
of LSDs. Since mechanisms of these processes and actions of
these factors have been excellently reviewed in past few years,
we will present them only briefly in this overview, describing
their crucial features and refereeing readers to previously
published articles for details.
Contrary to early assumptions on the mechanisms of LSDs,
it is now obvious that various symptoms appear not only due
to primary storage of undegraded compounds in lysosomes (in
fact, the primary lysosomal storage has been questioned as the
primary cause of these diseases; Platt et al. 2012), but also
because of secondary and tertiary effects. The primary storage
may affect activities of various lysosomal proteins, thus, defi-
ciency in degradation of different compounds and their sec-
ondary accumulation can occur. This, in turn, leads to further
disturbances in cell physiology, including activation of some
receptors by ligands that cannot do this under physiological
conditions, changes in receptors’ responses to specific medi-
ators, and modifications of signal transduction cascades due to
changes in functions of intracellular effectors (for a review, see
Ballabio and Gieselmann 2009). Then, various cellular stress
responses are activated, but due to continuous and progressive
accumulation of the primary and secondary storage com-
pounds they cannot restore the physiological balance and
rescue the cells. Thus, not only cellular but also systemic
reactions are involved in the disease pathomechanism. The
pathological effects occurring at different levels of the organ-
ism organization, include, but are not restricted to, oxidative
stress, endoplasmic reticulum stress, defects in autophagy,
dysfunction of the Golgi apparatus, epigenetic factors, mito-
chondrial dysfunction, peroxisomal dysfunction, altered cal-
cium homeostasis, abnormal trafficking of various com-
pounds, inflammatory processes, autoimmune response, and
energy imbalance. These LSD-associated effects have been
described and discussed recently by other authors (Bellettato
and Scarpa 2010; Parkinson-Lawrence et al. 2010; Vitner et al.
2010; Filocamo and Morrone 2011; Hawkins-Salsbury et al.
2011; Schultz et al. 2011; Cox and Cachon-Gonzalez 2012;
Platt et al. 2012), therefore they will not be reviewed in detail
here.
It is obvious that different intensities of the above men-
tioned processes may significantly influence the phenotypes
of patients suffering from LSDs, thus modulating severity of
the disease. Moreover, external factors may contribute to
expression of the specific processes and responses. This may
be exemplified by microbial infections, which are more often
in LSD patients than in general population due to impaired
immunological reactions, changed cellular physiology and
others. Such an influence was described, for instance, in
MPS I, where atypical microbial infections of digestive tract
contributed considerably to severity of the disease, causing
frequent diarrhea and worsening of a general patient status
(Wegrzyn et al. 2005).
Specific processes affecting severity of particular LSDs
Although physiological processes and environmental factors
described in the preceding chapter may significantly influence
severities of various LSDs indeed, it is rather unlikely that
they are the only determinants responsible for different phe-
notypes of patients bearing the same mutations, including
siblings. If such a scenario were true, it should be possible to
manage the disease at the level of the attenuated form by
controlling these processes and factors, and very similar se-
verity of the disease should be observed among siblings that
bear the same mutation(s) and live together under very similar
conditions, which is definitely not the case. Therefore, one
may assume that there are processes specific to each disease
which can significantly modulate its course and severity.
Vast majority of LSDs results from an imbalance between
synthesis and degradation of particular compounds. While the
synthesis process is unaffected, the degradation is impaired
which leads to accumulation of certain substances in lyso-
somes. About a decade ago it was speculated that various
efficiencies of syntheses of particular compounds, which
may occur in human population, could significantly influence
severity of LSDs and result in different phenotypes of patients
bearing the same mutations in genes responsible for degrada-
tion of these compounds (Wegrzyn et al. 2004). More recent
studies on mechanisms of LSDs, described below, suggested
that this hypothesis may be potentially true.
Metachromatic leukodystrophy (MLD) is caused by deficien-
cy in arylsulfatase A (ASA) and accumulation of sulfated
glycosphingolipids, predominantly 3-O-sulfogalactosylceramide
(sulfatide). Neuronopathy of this disease is primarily due to
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demyelination of neurons. To learn about molecular mechanisms
of this disease, a mouse model was constructed in which a
homologue of the human Arsa gene, coding for ASA, has been
inactivated (Hess et al. 1996). Surprisingly, mice homozygous
for the knock-out (null) mutation (ASA-/-) did not reveal demy-
elination, and thus, characteristic symptoms of humanMLD, like
reduction in nerve conduction velocity, progressive paralysis, and
peripheral neuropathy were not observed in these mice (Wittke
et al. 2004). Such a model appeared to be of a limited usage in
studies on mechanisms of the human disease, therefore, further
work was necessary to make affected mice more similar to
patients suffering from MLD. It was demonstrated that overex-
pression of the gene coding for galactose-3-O-sulfotransferase-1,
an enzyme responsible for production of sulfatide, resulted in
effective demyelination of mouse neurons and appearance of
symptoms resembling those observed in the human disease
(Ramakrishnan et al. 2007). Interestingly, synthesis of sulfatide
in the galactose-3-O-sulfotransferase-1-overproducing ASA-/-
mice was only about 2–fold higher than that in the ASA-/-
mutant (Ramakrishnan et al. 2007; Matthes et al. 2012). This
indicated that relatively minor changes in efficiency of synthe-
sis of a particular compound may significantly influence sever-
ity of a lysosomal disease which arises from inefficient degra-
dation of this compound (substrate), including appearance of
neuronopathic symptoms when the synthesis is elevated.
Contrary to stimulation of synthesis of the substrate that
cannot be degraded in lysosomes, partial inhibition of produc-
tion of another substrate (HS), accumulated in: MPS IIIA and
MPS IIIB, caused improvement of biochemical parameters
and phenotypes of affected animals. This was demonstrated
by chemical impairment of HS synthesis by the use of either
rhodamine B ([9-(2-carboxyphenyl)-6-diethylamino-3-
xanthenylidene]-diethylammonium chloride) (Roberts
et al. 2006, 2007) or genistein (5, 7-dihydroxy-3- (4-
hydroxyphenyl)-4H -1-benzopyran-4-one) (Malinowska
et al. 2009, 2010). In those studies, biochemical parameters
of MPS IIIA and MPS IIIB mice were improved in treated
animals relative to untreated ones, including a decreased HS
storage in brain. Moreover, behavior of these animals, severe-
ly affected in the absence of treatment, could be improved
(Roberts et al. 2007) or even corrected (Malinowska et al.
2010). It was proposed that putative mechanisms of reduction
of HS storage due to impairment of its synthesis may include
dilution of already accumulated molecules in the processes of
cell growth and division, and action of endoglycosidases, like
heparanase, in combination with functional hydrolases oper-
ating at non-inhibited steps of the degradation (Banecka-
Majkutewicz et al. 2012).
Although the experiments with chemically impaired syn-
thesis of the substrate production might corroborate the con-
clusions made on the basis of studies on MLD animals, it
could not be excluded that the used compounds, rhodamine B
and/or genistein, might modify other processes, like oxidative
stress or inflammation. In this light, it is crucial to note that a
very interesting study on the MPS IIIAmouse model has been
reported recently (Lamanna et al. 2012). In this model, the
Sgsh gene, coding for sulfamidase, an enzyme required for
degradation of HS, was mutated. Such MPS IIIA mice devel-
oped symptoms similar to those found in the human disease,
including severe neuronopathy. These symptoms could be
significantly attenuated when animals were also heterozygotic
for additional mutation(s) in one or two genes coding for
enzyme(s) involved in HS synthesis, Ext1 and Ext2, which
resulted in at most 2-fold decrease in the rate of production of
this GAG. Therefore, reduction of HS by 30–50 % led to
significant decrease in severity of the disease, including ame-
lioration of the amount of disease-specific biomarker in the
brain (Lamanna et al. 2012).
The above described studies on mouse models of LSDs,
MPS IIIA and MPS IIIB, strongly suggested that expression
of specific symptoms of various diseases, including
neuronopathy, depends not only on dysfunction of an enzyme
involved in degradation of certain compound(s), but also on
efficiency of production of the substrate(s) that cannot be
efficiently degraded in lysosomes. More specifically, less
efficient production should result in less severe symptoms.
Do we have any evidence that similar phenomena may occur
in humans suffering from LSDs? A few years ago, a report
was published in which efficiency of GAG synthesis was
measured in fibroblasts of healthy persons and patients suf-
fering from various types of MPS (Piotrowska et al. 2009). In
both groups (healthy persons and MPS patients), a consider-
able variability in kinetics of GAG production was observed,
with the differences between the lowest and highest values
determined for different subjects as high as 10 times. There-
fore, it appears that a high natural variability in efficiency of
GAG synthesis occurs in the natural human population. This
has minor or negligible effects on physiology of persons with
fully functional lysosomal system, however, it may signifi-
cantly influence severity of a disease arising from impaired
GAG degradation. In fact, MPS patients with low efficiency
of GAG synthesis had milder phenotypes than those produc-
ing GAGs more efficiently, provided that detectable residual
activity of the deficient enzyme involved in GAG degradation
was found (Piotrowska et al. 2009). Therefore, one may
speculate that the hypothesis made on the basis on studies
on animal models might be also valid for humans. Obviously,
there is a question whether the hypothesis based on the
examples provided above, and concerning particular dis-
eases, can be extrapolated to other LSDs? For example, to
our knowledge, there are no published results demonstrat-
ing a role for biosynthetic pathways in final levels of the
storage in patients suffering from sphingolipidoses, a
group of LSD (see recent review by Schuchman and
Simonaro 2013). Thus, further testing of the presented
hypothesis is deserved.
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Concluding remarks
Genotype-phenotype correlations in LSDs are clear for some
types of mutations, particularly when null mutations occur in
both alleles of the affected gene (or in the only allele in males
suffering from X-linked LSDs). However, phenotypes of pa-
tients bearing mutations resulting in residual activities of
affected enzymes depend on other factors, particularly various
stresses caused by different agents (e.g. oxidative stress, en-
doplasmic reticulum stress, defects in autophagy, altered cal-
cium homeostasis, abnormal trafficking of various compound,
inflammatory processes, autoimmune response, and energy
imbalance). The summary on factors and processes determin-
ing severity of LSDs is presented schematically in Fig. 1. In
fact, currently we are not able to precisely determine the level
of importance of particular factors or processes in disease
development. Nevertheless, it is tempting to speculate that
kinetics of synthesis of substrates that cannot be efficiently
degraded may be of special importance for expression of
disease symptoms, especially neuronopathic ones. Since a
high variability in the levels of synthesis of at least some
lysosomally-degraded compounds occurs in human popula-
tion, we propose a hypothesis that this parameter may be of
special importance in determination of phenotypes of a large
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group of patients suffering from LSDs. However, since exper-
imental data leading to this hypothesis are available only for
some of LSDs, it remains to be elucidated whether similar
mechanisms might operate in other diseases from this group.
Acknowledgments We apologize our colleagues whose works were
not cited due to space limitation and an overview character of this article.
This work was supported by National Science Center (Poland) (project
grants N N301 668540 and 2011/01/B/NZ1/03686).
Conflict of interest The authors declare no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Arfi A, Richard M, Scherman D (2012) Innovative therapeutic ap-
proaches for improving patient life condition with a neurological
lysosomal disease. In: Tan U (ed) Latest findings in intellectual and
developmental disabilities research. InTech, Rijeka, pp 177–206
Ballabio A, Gieselmann V (2009) Lysosomal disorders: from storage to
cellular damage. Biochim Biophys Acta 1793:684–696
Banecka-Majkutewicz Z, Jakobkiewicz-Banecka J, Gabig-Ciminska M,
Wegrzyn A, Wegrzyn G (2012) Putative biological mechanisms of
efficiency of substrate reduction therapies formucopolysaccharidoses.
Arch Immunol Ther Exp 60:461–468
Bellettato CM, Scarpa M (2010) Pathophysiology of neuropathic lyso-
somal storage disorders. J Inherit Metab Dis 33:347–362
Biegstraaten M, van Schaik IN, Aerts JMFG, Langeveld M, Mannens
MMAM, Bour LJ, Sidransky E, Tayebi N, Fitzgibbon E, Hollak
CEM (2011) A monozygotic twin pair with highly discordant
Gaucher phenotypes. Blood Cells Mol Dis 46:39–41
Brands MM, Hoogeveen-Westerveld M, Kroos MA, Nobel W, Ruijter
GJ, Ozkan L, Plug I, Grinberg D, Vilageliu L, Halley DJ, van der
Ploeg AT, Reuser AJ (2013) Mucopolysaccharidosis type VI
phenotypes-genotypes and antibody response to galsulfase.
Orphanet J Rare Dis 8:51
Campos D, Monaga M (2012) Mucopolysaccharidosis type I: current
knowledge on its pathophysiological mechanisms. Metab Brain Dis
27:121–129
Chkioua L, Khedhiri S, Turkia HB, Tcheng R, Froissart R, Chahed H,
Ferchichi S, Ben Dridi MF, Vianey-Saban C, Laradi S, Miled A
(2011) Mucopolysaccharidosis type I: molecular characteristics of
two novel alpha-L-iduronidase mutations in Tunisian patients.
Diagn Pathol 6:47
Cox TM, Cachon-Gonzalez MB (2012) The cellular pathology of lyso-
somal diseases. J Pathol 226:241–254
EckhardtM (2010) Pathology and current treatment of neurodegenerative
sphingolipidoses. Neuromol Med 12:362–382
Filocamo M, Morrone A (2011) Lysosomal storage disorders: molecular
basis and laboratory testing. Hum Genomics 5:156–169
Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK,
Schiffmann R, Sidransky E (2005) Divergent phenotypes in
Gaucher disease implicate the role of modifiers. J Med Genet 42:e37
Hawkins-Salsbury JA, Reddy AS, Sands MS (2011) Combination ther-
apies for lysosomal storage disease: is the whole greater than the
sum of its parts? Human Mol Genet 20:R54–R60
Hess B, Saftig P, Hartmann D, Coenen R, Lüllmann-Rauch R, Goebel
HH, Evers M, von Figura K, D’Hooge R, Nagels G, De Deyn P,
Peters C, Gieselmann V (1996) Phenotype of arylsulfatase A-
deficient mice: relationship to human metachromatic leukodystro-
phy. Proc Natl Acad Sci U S A 93:14821–14826
Jardim LB, Villanueva MM, de Souza CF, Netto CB (2010) Clinical
aspects of neuropathic lysosomal storage disorders. J Inherit Metab
Dis 33:315–329
Jurecka A, Golda A, Opoka-Winiarska V, Piotrowska E, Tylki-
Szymanska A (2011) Mucopolysaccharidosis type VI (Maroteaux-
Lamy syndrome) with a predominantly cardiac phenotype. Mol
Genet Metab 104:695–699
Jurecka A, Zakharova E, Cimbalistiene L, Gusina N, Kulpanovich A,
Golda A, Opoka-Winiarska V, Piotrowska E, Voskoboeva E, Tylki-
SzymanskaA (2013)Mucopolysaccharidosis typeVI: a predominant-
ly cardiac phenotype associated with homozygosity for p.R152W
mutation in the ARSB gene. Am J Med Genet A 161:1291–1299
Koprivica V, Stone DL, Park JK, CallahanM, Frisch A, Cohen IJ, Tayebi
N, Sidransky E (2000) Analysis and classification of 304 mutant
alleles in patients with type 1 and type 3 Gaucher disease. Am J
Hum Genet 66:1777–1786
Korf BR, Rehm HL (2013) New approaches to molecular diagnosis.
JAMA 309:1511–1521
KroosM, Hoogeveen-WesterveldM, van der Ploeg A, Reuser AJJ (2012)
The genotype–phenotype correlation in Pompe disease. Am J Med
Genet Part C Semin Med Genet 160C:59–68
Lachmann RH, Grant IR, Halsall D, Cox TM (2004) Twin pairs showing
discordance of phenotype in adult Gaucher’s disease. Q J Med 97:
199–204
Lamanna WC, Lawrence R, Sarrazin S, Lameda-Diaz C, Gordts PL,
Moremen KW, Esko JD (2012) A genetic model of substrate reduc-
tion therapy for mucopolysaccharidosis. J Biol Chem 287:36283–
36290
Lashford LS, Fairbairn LJ, Wraith JE (1999) Lysosomal storage disor-
ders. In: Meager A (ed) Gene therapy technologies, applications and
regulations, John Wiley & Sons Ltd, pp. 267–290
Lippi G, Favaloro EJ (2009) The missing link between genotype, pheno-
type and clinics. Biochem Med 19:137–145
Lyonnet S, Feingold J, Frezal J (2006) Genotype-phenotype relation-
ships. Encyclopedia of life sciences. John Wiley & Sons, Ltd. doi:
10.1002/9780470015902.a0005476
Malinowska M, Wilkinson FL, Bennett W, Langford-Smith KJ, O’Leary
HA, Jakóbkiewicz-Banecka J, Wynn R, Wraith JE, Węgrzyn G,
Bigger BW (2009) Genistein reduces lysosomal storage in periph-
eral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 98:
235–242
Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A,
Brown JR, Crawford BE, Vanier MT, Grynkiewicz G, Wynn RF,
Wraith JE, Węgrzyn G, Bigger BW (2010) Genistein improves
neuropathology and corrects behaviour in a mouse model of neuro-
degenerative metabolic disease. PLoS One 5:e14192
Matthes F, Stroobants S, Gerlach D, Wohlenberg C, Wessig C, Fogh J,
Gieselmann V, Eckhardt M, D’Hooge R,Matzner U (2012) Efficacy
of enzyme replacement therapy in an aggravated mouse model of
metachromatic leukodystrophy declines with age. Hum Mol Genet
21:2599–2609
Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA,
Sidransky E, Grabowski GA, Krainc D (2011) Gaucher disease
glucocerebrosidase and α-synuclein form a bidirectional pathogenic
loop in synucleinopathies. Cell 146:37–52
Michelakakis H, Moraitou M, Dimitriou E, Santamaria R, Sanchez G,
Gort L, Chabas A, Grinberg D, Dassopoulou M, Fotopoulos S,
Vilageliu L (2006) Homozygosity for the double D409H + H255Q
allele in type II Gaucher disease. J Inherit Metab Dis 29:591
Muenzer J (2011) Overview of the mucopolysaccharidoses.
Rheumatology 50(Suppl 5):v4–v12
Olanow CW, Brundin P (2013) Parkinson’s disease and alpha synuclein:
is Parkinson’s disease a prion-like disorder? Mov Disord 28:31–40
Metab Brain Dis
Parkinson-Lawrence EJ, Shandala T, Prodoehl M, Plew R, Borlace GN,
Brooks DA (2010) Lysosomal storage disease: revealing lysosomal
function and physiology. Physiology 25:102–115
Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A,
Czartoryska B, Wegrzyn A, Wegrzyn G (2009) Correlation between
severity of mucopolysaccharidoses and combination of the residual
enzyme activity and efficiency of glycosaminoglycan synthesis.
Acta Paediatr 98:743–749
Platt FM, BolandB, van der Spoel AC (2012) The cell biology of disease:
lysosomal storage disorders: the cellular impact of lysosomal dys-
function. J Cell Biol 199:723–734
Ramakrishnan H, Hedayati KK, Lullmann-Rauch R, Wessig C, Fewou
SN, Maier H, Goebel HH, Gieselmann V, Eckhardt M (2007)
Increasing sulfatide synthesis in myelin-forming cells of
arylsulfatase A-deficient mice causes demyelination and neurolog-
ical symptoms reminiscent of human metachromatic leukodystro-
phy. J Neurosci 27:9482–9490
Ries M, Gal A (2006) Genotype–phenotype correlation in Fabry disease.
In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease:
perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford,
Chapter 34
Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S (2006)
Inhibition of glycosaminoglycan synthesis using a rhodamine B in a
mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 60:309–
314
Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S (2007)
Improvement in behaviour after substrate deprivation therapy with
rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 92:
115–121
Saito S, Ohno K, Sekijima M, Suzuki T, Sakuraba H (2012)
Database of the clinical phenotypes, genotypes and mutant
arylsulfatase B structures in mucopolysaccharidosis type VI.
J Hum Genet 57:280–282
Schuchman EH, Simonaro CM (2013) The genetics of sphingolipid
hydrolases and sphingolipid storage diseases. Handb Exp
Pharmacol 215:3–32
Schultz ML, Tecedor L, Chang M, Davidson BL (2011) Clarifying
lysosomal storage diseases. Trends Neurosci 34:401–410
Sidransky E (2004) Gaucher disease: complexity in a “simple” disorder.
Mol Genet Metabol 83:6–15
Sidransky E (2005) Gaucher disease and parkinsonism.Mol GenetMetab
84:302–304
Silverman LM, Mahadevan MS (2005) Genotype-phenotype correla-
tions: assessing the influence of sequence variants on the clinical
phenotype. Clin Chem 51:8
Terlato NJ, Cox GF (2003) Can mucopolysaccharidosis type I disease
severity be predicted based on a patient’s genotype? A comprehensive
review of the literature. Genet Med 5:286–294
Valayannopoulos V, Nicely H, Harmatz P, Turbeville S (2010)
Mucopolysaccharidosis VI. Orphanet J Rare Dis 5:24
Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ,Wijburg FA (2008)
Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31:240–252
Verity C, Winstone AM, Stellitano L, Will R, Nicoll A (2010) The
epidemiology of progressive intellectual and neurological deteriora-
tion in childhood. Arch Dis Child 95:361–364
Vitner EB, Futerman AH (2013) Neuronal forms of Gaucher disease.
Handb Exp Pharmacol 216:405–419
Vitner EB, Platt FM, Futerman AH (2010) Common and uncommon
pathogenic cascades in lysosomal storage diseases. J Biol Chem
285:20423–20427
Wegrzyn G,Wegrzyn A, Tylki-Szymanska A (2004) A general model for
genetic regulation of turnover of glycosaminoglycans suggests a
possible procedure for prediction of severity and clinical progress
of mucopolysaccharidoses. Med Hypotheses 62:986–992
Wegrzyn G, Kurlenda J, Liberek A, Tylki-Szymanska A, Czartoryska B,
Piotrowska E, Jakóbkiewicz-Banecka J,WegrzynA (2005)Atypical
microbial infections of digestive tract may contribute to diarrhea in
mucopolysaccharidosis patients: a MPS I case study. BMC Pediatr
5:9
Wegrzyn G, Jakobkiewicz-Banecka J, Narajczyk M, Wisniewski
A, Piotrowska E, Gabig-Ciminska M, Kloska A, Słominska-
Wojewodzka M, Korzon-Burakowska A, Wegrzyn A (2010)
Why are behaviors of children suffering from various
neuronopathic types of mucopolysaccharidoses different?
Med Hypoth 75:605–609
Wijburg FA, Wegrzyn G, Burton BK, Tylki-Szymanska A (2013)
Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdi-
agnosis of idiopathic developmental delay, attention deficit/
hyperactivity disorder or autism spectrum disorder. Acta Paediatr
102:462–470
Wittke D, Hartmann D, Gieselmann V, Lullmann-Rauch R (2004)
Lysosomal sulfatide storage in the brain of arylsulfatase A-
deficient mice: cellular alterations and topographic distribution.
Acta Neuropathol 108:261–271
Metab Brain Dis
